Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Net Income (2016 - 2024)

Historic Net Income for Summit Therapeutics (SMMT) over the last 8 years, with Q4 2024 value amounting to -$65.6 million.

  • Summit Therapeutics' Net Income fell 8122.89% to -$65.6 million in Q4 2024 from the same period last year, while for Sep 2025 it was -$65.6 million, marking a year-over-year increase of 3237.67%. This contributed to the annual value of -$234.7 million for FY2024, which is 6183.55% up from last year.
  • Latest data reveals that Summit Therapeutics reported Net Income of -$65.6 million as of Q4 2024, which was down 8122.89% from -$60.8 million recorded in Q3 2024.
  • In the past 5 years, Summit Therapeutics' Net Income registered a high of -$9.0 million during Q1 2020, and its lowest value of -$65.6 million during Q4 2024.
  • For the 4-year period, Summit Therapeutics' Net Income averaged around -$32.8 million, with its median value being -$20.5 million (2023).
  • Its Net Income has fluctuated over the past 5 years, first skyrocketed by 124.15% in 2020, then crashed by 19685.73% in 2024.
  • Summit Therapeutics' Net Income (Quarter) stood at -$9.0 million in 2020, then tumbled by 125.55% to -$20.3 million in 2022, then plummeted by 78.38% to -$36.2 million in 2023, then crashed by 81.23% to -$65.6 million in 2024.
  • Its last three reported values are -$65.6 million in Q4 2024, -$60.8 million for Q3 2024, and -$36.2 million during Q4 2023.